REGN

Regeneron outlines multi‑indication C5 strategy
Regeneron positions an RNA‑plus‑antibody combo to unlock multibillion markets; gMG near‑term focus, PNH readout due Q4.
Apr 25, 2026
5 min read
Institutions Shift Positions in Major Blue-Chip Stocks
Portfolio reshuffling boosts insurers and biotech; analysts back health names while P&G shows investor uncertainty.
Apr 17, 2026
5 min read
Amgen Rides Renewed GLP-1 Obesity Momentum
Amgen (AMGN) is now being treated in positioning as an emerging GLP-1 obesity and diabetes play, with investors increasingly framing the stock around its obesity pipeline rather than only its legacy...
Apr 9, 2026
1 min read
Biotech ETFs Flash Classic Reversal Signal
Biotech is emerging as a leadership pocket, with SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU) showing notable relative strength into a session where both surged...
Apr 1, 2026
2 min read
Japan clears Dupixent for bullous pemphigoid
Sanofi's Dupixent wins Japanese nod for rare blistering disease after strong Phase 2/3 results; Q1 memo out.
Mar 24, 2026
4 min read
Goldman’s Top Healthcare Picks Gain Fresh Catalysts
Clinical wins and analyst upgrades spark renewed momentum across big pharma and biotech stocks.
Mar 15, 2026
4 min read
Institutions Boost Stakes in Regeneron
Mixed institutional flows reshape Regeneron momentum after a stronger quarter and upgraded outlook.
Mar 15, 2026
4 min read
Institutional Moves in Major U.S. Equities
Institutional reallocations and exec stock sales prompt analysts to keep conservative stances.
Mar 12, 2026
4 min read
2025 Valuation Insights: Spotify, Aker BP, and Key Growth Stocks
Spotify's growth shines amid valuation risks; Aker BP's gains face premium multiples in mixed market outlook.
Dec 7, 2025
5 min read